Our clinical investigations revealed a strong link between pericyte‐IL32 expression and prognosis in EGFR‐mutated NSCLC patients undergoing third‐generation TKI treatment, suggesting it may indicate their response to treatment. Here, EGFR is linked to non-small cell lung carcinoma.